KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $1.3 billion.

  • Jazz Pharmaceuticals' Cash & Equivalents fell 4021.69% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 4021.69%. This contributed to the annual value of $2.4 billion for FY2024, which is 6018.38% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Cash & Equivalents of $1.3 billion as of Q3 2025, which was down 4021.69% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Cash & Equivalents registered a high of $2.4 billion during Q4 2024, and its lowest value of $490.8 million during Q1 2022.
  • Moreover, its 5-year median value for Cash & Equivalents was $1.3 billion (2023), whereas its average is $1.3 billion.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Cash & Equivalents soared by 19896.34% in 2021, and later crashed by 7659.94% in 2022.
  • Quarter analysis of 5 years shows Jazz Pharmaceuticals' Cash & Equivalents stood at $591.4 million in 2021, then surged by 49.04% to $881.5 million in 2022, then skyrocketed by 70.88% to $1.5 billion in 2023, then surged by 60.18% to $2.4 billion in 2024, then plummeted by 45.04% to $1.3 billion in 2025.
  • Its Cash & Equivalents was $1.3 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.9 billion in Q1 2025.